Cargando…

Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE’s recommendations

Detalles Bibliográficos
Autores principales:	Gavan, Sean P, Jani, Meghna, Bluett, James, Payne, Katherine, Barton, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474855/ https://www.ncbi.nlm.nih.gov/pubmed/32914047 http://dx.doi.org/10.1093/rap/rkaa023

Ejemplares similares

A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice
por: Jani, Meghna, et al.
Publicado: (2016)

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis
por: Bluett, James, et al.
Publicado: (2017)

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score
por: Gilani, Syed SA, et al.
Publicado: (2020)

Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?
por: Curry, Philippa D. K., et al.
Publicado: (2022)

Management of rheumatoid arthritis: summary of NICE guidance
por: Deighton, Chris, et al.
Publicado: (2009)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Management of the Rheumatoid Arthritis Patient with Interstitial Lung Disease
por: Jani, Meghna, et al.
Publicado: (2017)

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, J, et al.
Publicado: (2014)

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
por: Jani, Meghna, et al.
Publicado: (2014)

Pharmacogenetics of Treatment Response in Psoriatic Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
por: Bogunia-Kubik, Katarzyna, et al.
Publicado: (2021)

Provision of NICE-recommended varicose vein treatment in the NHS
por: Hitchman, Louise H, et al.
Publicado: (2022)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
por: Said, Cynthia, et al.
Publicado: (2013)

Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment
por: Vass, Caroline M, et al.
Publicado: (2021)

Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis
por: Desilet, Luke W., et al.
Publicado: (2020)

Updated recommendations: an assessment of NICE clinical guidelines
por: Martínez García, Laura, et al.
Publicado: (2014)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

The Cytokine Network in Rheumatoid Arthritis: Definition of TNFα as a Therapeutic Target
por: Feldmann, Marc
Publicado: (1996)

Trends in procedures for infertility and caesarean sections: was NICE disinvestment guidance implemented? NICE recommendation reminders
por: Chamberlain, Charlotte A, et al.
Publicado: (2013)

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Bone and TNF in rheumatoid arthritis: clinical implications
por: Manara, Maria, et al.
Publicado: (2015)

Rheumatoid arthritis treatment with TNF inhibitors and alternative procedures in case of its failure – results of the Polish survey in the context of EULAR recommendations
por: Tłustochowicz, Małgorzata, et al.
Publicado: (2015)

Factors that influence rheumatologists’ anti-tumor necrosis factor alpha prescribing decisions: a qualitative study
por: Gavan, Sean P., et al.
Publicado: (2019)

Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis
por: Spinelli, F. R., et al.
Publicado: (2013)

Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2016)

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
por: Lopez-Rodriguez, Rosario, et al.
Publicado: (2018)

Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-α Inhibitors
por: Szeremeta, Anna, et al.
Publicado: (2020)

Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: OIiver, James, et al.
Publicado: (2021)

Consistency of recommendations for pharmacotherapy of rheumatoid arthritis
por: Hu, Yue, et al.
Publicado: (2022)

TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients
por: Al-Rayes, Hannan, et al.
Publicado: (2011)

The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis
por: Vial, Gaelle, et al.
Publicado: (2021)

Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial
por: Durez, Patrick, et al.
Publicado: (2014)

Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: Oliver, James, et al.
Publicado: (2021)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
por: Taylor, Peter C., et al.
Publicado: (2023)

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both?
por: Zamri, Fatima, et al.
Publicado: (2020)

What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
por: Mehta, Puja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_im01gupfrajks8d37hl7gattp7